IFNA1 and myeloid sarcoma: It was observed that without GA, overall disease activity was higher in HLA-A∗03:01 carriers of most cohorts and future studies are needed to assess whether HLA-A∗03:01 might contribute to worse disease prognosis in patients with MS under treatments other than IFN.